[Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study].

Fu, Yi; Mi, Weifeng; Li, Lingzhi; Zhang, Hongyan; Wang, Jia; Cheng, Wenjun; Sun, Lizhou; Li, Lingjiang; Xie, Shiping; Zhang, Jinbei

Fu, Yi; Mi, Weifeng; Li, Lingzhi; Zhang, Hongyan; Wang, Jia; Cheng, Wenjun; Sun, Lizhou; Li, Lingjiang; Xie, Shiping; Zhang, Jinbei.

Affiliation

Fu Y; Peking University Institute of Mental Health, Beijing 100191, China.
Zhang H; Email: sally_zhy@sina.com.

Zhonghua Fu Chan Ke Za Zhi ; 49(7): 506-9, 2014 Jul.

Article in Zh | MEDLINE | ID: mdl-25327732

Subject(s)

Androstenes/therapeutic use; Contraceptives, Oral, Combined/therapeutic use; Ethinyl Estradiol/therapeutic use; Premenstrual Dysphoric Disorder/drug therapy; Androstenes/adverse effects; Contraceptives, Oral; Contraceptives, Oral, Combined/adverse effects; Double-Blind Method; Ethinyl Estradiol/adverse effects; Female; Humans; Menorrhagia; Metrorrhagia; Premenstrual Syndrome; Safety; Severity of Illness Index; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Health context: 1_ASSA2030 Database: MEDLINE Main subject: Contraceptives, Oral, Combined / Ethinyl Estradiol / Premenstrual Dysphoric Disorder / Androstenes Type of study: Clinical_trials Limits: Female / Humans Language: Zh Journal: Zhonghua Fu Chan Ke Za Zhi Year: 2014 Document type: Article

Search on Google

XML

PubMed Links